For Enquiry : +(91) 9923599971

Sun Pharmaceutical Industries Limited

DATE OPEN HIGH LOW CLOSE VOLUME
19-10-2018 591.9000 611.5000 590.1000 609.9500 4841805
17-10-2018 609.4000 609.4000 591.0000 593.4500 2629035
16-10-2018 601.9500 612.0000 592.8500 602.7000 3557343
15-10-2018 593.7000 603.4500 586.6500 599.9500 3422475
12-10-2018 591.1000 597.7500 582.6500 590.6000 5795641
11-10-2018 590.0000 603.2500 582.7000 586.7000 4591533
10-10-2018 610.0000 619.5000 593.0000 602.9500 5566798
09-10-2018 608.0000 617.3000 597.6000 609.7500 4516779
08-10-2018 592.0000 608.7500 589.1000 604.2500 4400199
05-10-2018 595.0000 616.3500 591.0500 597.9500 6804502
04-10-2018 618.0000 620.7500 590.8500 599.0500 4851894
03-10-2018 636.5000 640.7500 618.5000 620.8500 4723773
01-10-2018 624.0000 639.0000 610.0000 634.7000 5527208
28-09-2018 630.0000 636.3500 616.1000 623.2500 6693066
27-09-2018 641.7000 643.9500 625.2000 631.2500 4070395
26-09-2018 649.8000 649.8000 632.5500 639.8500 4850782
25-09-2018 624.1000 645.0000 624.0500 641.1000 7213759
24-09-2018 638.0000 642.9500 616.0000 624.0000 5305739
21-09-2018 650.0000 655.0000 614.5000 634.9000 9635852
19-09-2018 651.9500 657.2500 641.6000 648.8500 7659788
18-09-2018 646.4000 655.7000 640.5000 642.5000 5780144
17-09-2018 661.0000 668.2500 644.2000 646.2000 6264996
14-09-2018 665.0000 670.9000 658.0000 665.2500 7444874
12-09-2018 625.0000 654.4000 620.1000 649.9000 11215125
11-09-2018 643.0000 649.4000 627.5500 630.4000 8273963
10-09-2018 656.5000 667.2500 635.3500 638.0000 9930755
07-09-2018 650.0000 670.0000 640.0000 664.2500 22074525
06-09-2018 668.0000 679.3000 663.2500 677.4000 7815292
05-09-2018 654.1000 671.8000 653.7500 663.7500 9140409
04-09-2018 658.0000 663.4500 645.1500 655.3500 7989190
03-09-2018 658.8000 673.5000 651.2500 656.2000 12185947
31-08-2018 643.4500 659.4000 643.3000 652.8500 12972927
30-08-2018 623.5000 642.0000 622.1500 639.9500 9022572
29-08-2018 623.9000 631.0000 616.8000 621.2500 4435825
28-08-2018 625.0000 633.4500 619.1000 621.2000 4181613
27-08-2018 632.3000 636.6000 620.6500 621.8000 8253456
24-08-2018 638.2500 639.8000 618.7000 629.8000 7909136
23-08-2018 639.9000 645.5000 634.3000 639.6500 8942755
21-08-2018 626.9000 639.4500 620.5000 635.4000 7752348
20-08-2018 625.0000 630.9500 620.2500 626.3500 9494515
17-08-2018 623.0000 633.4000 619.0000 623.5000 14161255
16-08-2018 610.0000 621.7000 602.2000 619.7000 25169096
14-08-2018 565.5000 610.0000 560.1000 601.8000 25001972
13-08-2018 556.9000 567.5000 552.6000 563.9000 3254839
10-08-2018 566.1000 569.7000 548.8500 554.0000 6086714
09-08-2018 575.2000 584.9000 563.0500 571.4500 4595269
08-08-2018 570.0000 578.3500 564.3000 574.0000 2970652
07-08-2018 580.4500 582.5000 568.2500 569.7000 3076068
06-08-2018 586.5000 593.4000 575.1000 576.1500 3867267
03-08-2018 583.9000 589.4000 583.8500 585.8500 3298774
02-08-2018 575.9000 587.5500 575.3000 580.4000 5898107
01-08-2018 570.0000 576.8000 563.8000 574.6500 3672172
31-07-2018 562.5000 575.7500 560.1500 568.5000 5998010
30-07-2018 555.3000 566.7500 551.9500 562.7000 3441224
27-07-2018 555.9000 561.0000 553.2500 557.0500 2638153
26-07-2018 553.9500 563.8000 551.5000 555.4000 3113443
25-07-2018 566.4000 567.3500 555.5000 558.1500 2161490
24-07-2018 562.1000 568.5000 559.0500 562.7000 2480730
23-07-2018 562.7000 567.0000 557.5000 561.7500 2459719
20-07-2018 545.0000 563.0000 545.0000 560.1000 2702091
19-07-2018 552.4000 553.8000 542.2500 544.9500 2767826
18-07-2018 554.9500 559.2000 542.8500 549.9000 5720388
17-07-2018 535.0000 551.7500 533.0000 548.6500 3699579
16-07-2018 559.5000 560.0000 530.7000 533.9500 4267330
13-07-2018 566.8000 567.0000 557.0500 559.7500 2012823
12-07-2018 563.0000 570.7000 558.0000 564.4500 3736611
11-07-2018 564.9500 569.7000 559.6000 560.7500 3519985
10-07-2018 569.0000 572.0000 558.0000 563.9500 4594276
09-07-2018 560.6000 572.6000 560.6000 568.8000 4117856
06-07-2018 567.4000 573.2500 555.0000 558.1000 5609846
05-07-2018 581.0000 581.0000 564.9000 566.9500 3833300
04-07-2018 576.0000 588.8500 573.0500 579.3000 9406196
03-07-2018 564.8000 576.8000 560.7000 573.6000 5950013
02-07-2018 566.3000 572.8500 558.5000 563.1500 4132132
29-06-2018 569.0000 571.9000 560.1500 564.0000 4416940
28-06-2018 577.7500 583.2000 564.2000 567.3000 5516028
27-06-2018 577.0000 581.7000 568.5000 576.9000 8539318
26-06-2018 571.3500 576.5000 565.8000 572.9500 4726890
25-06-2018 576.9000 592.0000 567.9500 571.8000 14303449
22-06-2018 553.0000 581.8000 547.6500 577.2500 9935404
21-06-2018 565.0000 567.4500 552.6000 554.5000 3243433
20-06-2018 559.0000 565.7000 553.1000 564.1000 4435880
19-06-2018 570.0000 576.5000 558.3500 559.9500 6719183
18-06-2018 572.0000 578.3000 563.9000 570.1000 6090932
15-06-2018 562.0000 573.8500 561.0000 571.3000 15166730
14-06-2018 546.0000 562.0000 542.0000 559.2500 12154425
13-06-2018 552.2000 560.9500 542.3500 546.3000 20167822
12-06-2018 535.7000 544.9500 531.3500 540.4500 8140874
11-06-2018 530.0000 544.0000 526.1500 535.7000 16452353
08-06-2018 487.0000 533.6500 486.2500 528.2500 29224236
07-06-2018 490.6500 493.9000 485.5500 488.7500 2197858
06-06-2018 476.9000 492.2000 473.1000 489.8500 4126448
05-06-2018 476.1500 483.2500 470.1500 473.5000 3076737
04-06-2018 486.0000 490.8000 476.8000 478.6000 2995860
01-06-2018 485.0000 489.5500 479.1000 484.3500 3793797
31-05-2018 494.9000 496.0000 472.9000 480.3500 18790216
30-05-2018 494.9000 503.7000 492.3500 494.5500 3851368
29-05-2018 496.6000 509.9500 490.0500 499.5000 8258927
28-05-2018 485.0000 504.9500 480.0000 499.7000 16007675
25-05-2018 465.5000 469.4000 456.0000 466.4500 4971624

SUNPHARMA NEWS

  • Sun Pharma And SPARC Announce US FDA Approval Of XELPROS™ To Treat Open-angle Glaucoma Or Ocular Hypertension

    XELPROSTM 0.005% For Topical Ophthalmic Use Is The First And Only Benzalkonium Chloride-free Form Of Latanoprost

  • Sun Pharma Announces U.S. FDA Approval Of CEQUA™ To Treat Dry Eye Disease

    CEQUA 0.09% For Topical Ophthalmic Use Is The First And Only Dry Eye Treatment To Combine Cyclosporine A With Nanomicellar Technology

  • Sun Pharma First-quarter Profit Beats Estimates As U.S. Sales Climb

    (Reuters) - India's Largest Drugmaker Sun Pharmaceutical Industries Ltd Posted A First-quarter Profit On Tuesday, Beating Street Estimates, Helped By Stronger Sales In The United States. Net Profit Came ...

  • Sun Pharma Launches Novel Drug Kapspargo Sprinkle™ In USA

    First USFDA Approved, Extended-release Sprinkle Formulation Of Metoprolol Succinate Indicated For Treatment Of Patients With Hypertension, Angina Pectoris And Heart Failure

  • DUSA Pharmaceuticals, Inc. Files Lawsuit Against Biofrontera Inc. For Patent Infringement, Trade Secret Misappropriation, And Tortious Interference

    PRINCETON, New Jersey And MUMBAI, India , July 11, 2018 /PRNewswire/ -- DUSA Pharmaceuticals, Inc., ("DUSA") A Wholly Owned Subsidiary Of Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO), ...

  • What Are Analysts Saying About Sun Pharmaceutical Industries Limited’s (NSE:SUNPHARMA) Growth?

    Sun Pharmaceutical Industries Limited’s (NSE:SUNPHARMA) Latest Earnings Update In March 2018 Indicated That The Business Endured A Immense Headwind With Earnings Deteriorating By -68.96%. Below Is My Commentary, Albeit VeryRead More...

  • Drugmaker Sun Pharma Says Halol Plant Has Gained U.S. Clearance

    Supply Restrictions Imposed On India's Largest Drugmaker Sun Pharmaceutical Industries By U.S. Regulators Have Been Lifted, The Company Said On Tuesday, Removing A Major Drag On Its Share Price. Sun Will Now Be Able To Resume Shipments Of Drugs Made At Its Halol Factory In Western India, Which Contributed As Much As 15 Percent To Its U.S. Revenue In 2015. The Restrictions On Some Drugs Made At The Site Had Been Imposed After An Inspection Revealed Quality Control Failures.

  • FDA Clears Way For Sun Pharma To Sell New Drugs From Key Plant

    The U.S. Drug Regulator Has Cleared A Key Plant For Sun Pharmaceutical Industries Ltd., A Move That May Allow India’s Biggest Drugmaker To Renew Product Launches From The Facility After A Two And A Half Year Ban. The U.S. Food And Drug Administration Has Closed Its Inspection Of The Halol Plant After The Issues Contained In A 2015 Warning Letter Were Addressed, Sun Pharma Said In A Filing To Exchanges On Tuesday. In February The FDA Noted Three Observations Of Potential Manufacturing Violations, Which Sun Pharma Said It Was Addressing.

  • Morning News Call - India, May 28

    To Access The Newsletter, Click On The Link: Http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_05282018.pdf If You Would Like To Receive This Newsletter Via Email, Please Register ...

  • Sun Pharma Warns U.S. Pricing Pressure To Hit 2019 Profit

    Makers Of Generic Drugs Have Seen Poor Sales As Uncertainty Grows In The Global Market For Copycat Drugs Due To Rising Competition And Pricing Scrutiny In The World's Largest Healthcare Market. The Warning Compounds Problems At Sun, Which Has Been Struggling To Get Clearance For Its Factories That Are Under U.S. Supply Bans Due To Quality Control Failures. It Now Plans To Reduce Its Research Spend On Some Generic Drug Projects That Have Become "unviable", Dilip Shanghvi, The Company's Founder And Managing Director, Said On A Conference Call With Analysts.

  • India's Sun Pharma Warns U.S. Pricing Pressure To Hit 2019 Profit

    India's Largest Drugmaker Sun Pharmaceutical Industries Ltd Said On Friday It Expects Its 2019 Revenue To Come In Short Of Analysts' Expectations Due To Pricing Pressure In Its Main Market, The United States. Makers Of Generic Drugs Have Seen Poor Sales As Uncertainty Grows In The Global Market For Copycat Drugs Due To Rising Competition And Pricing Scrutiny In The World's Largest Healthcare Market. The Warning Compounds Problems At Sun, Which Has Been Struggling To Get Clearance For Its Factories That Are Under U.S. Supply Bans Due To Quality Control Failures.

  • Sun Pharma Announces USFDA Approval Of YONSA® (abiraterone Acetate) To Treat Metastatic Castration-Resistant Prostate Cancer In Combination With Methylprednisolone

    Sun Pharmaceutical Industries Ltd. And Churchill Pharmaceuticals, LLC.

  • BRIEF-Sun Pharmaceutical Industries' Unit Raises Stake In Ranbaxy Malaysia

    April 18 (Reuters) - Sun Pharmaceutical Industries Ltd : * UNIT RAISED STAKE IN RANBAXY MALAYSIA VIA FURTHER PURCHASE OF 394,404 SHARES OF RANBAXY MALAYSIA * SAYS POST SHARE PURCHASE, CO'S TOTAL HOLDING ...

  • Sun Pharmaceutical Announces First U.S. Approval For Novel Drug

    Sun Pharmaceutical Industries Ltd., India’s Largest Drug Maker, Has Announced Its First U.S. Approval For An Innovative Medicine, Marking A Milestone In The Company’s Bid To Diversify Out Of Generic Drugs ...

  • Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA): Time For A Financial Health Check

    Investors Pursuing A Solid, Dependable Stock Investment Can Often Be Led To Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA), A Large-cap Worth ₹1.24T. Doing Business Globally, Large Caps Tend To Have DiversifiedRead More...

  • Sun Pharma Quarterly Profit Plunges On Weak U.S. Sales

    Sun Pharma, Along With Other Indian Pharmaceutical Companies, Has Been Battling Increased Competition In The Generics Market And Greater Pricing Scrutiny In The United States. The Drugmaker Has Also Struggled As Some Of Its Products Were Banned From Sale In The United States Because The Factories That Made Them Did Not Meet U.S. Quality Standards. It Was Also Hit By Adjustments For U.S. Tax Reforms In The Third Quarter.

  • At INR557.45, Is Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) A Buy?

    Today We’re Going To Take A Look At The Well-established Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA). The Company’s Stock Saw A Double-digit Share Price Rise Of Over 10% In The PastRead More...

  • Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA): Does -56.99% Earnings Drop In A Year Reflect The Long-Term Trend?

    When Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) Announced Its Most Recent Earnings (30 September 2017), I Did Two Things: Looked At Its Past Earnings Track Record, Then Look At What IsRead More...

Technical Chart

Chat

Sharemarket Tips

Get 2 Rupay

Any Queries

Chat Now
Stock Market Advice

international markets

About us | Contact Us | Feedback | Disclaimer | Privacy Statement | Terms of Use | Financial Terms (Glossary) | FAQs

Copyright © 2018 Get2rupay. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of get2rupay.com is prohibited.